Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | OPA1 | O60313 | 1/20 | 0.40 |
| ▸ | EIF5B | O60841 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020595 | 0.81 | HTR2A (0.42) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2020543 | 0.80 | HSD17B10 (0.44) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2017958 | 0.79 | HPGD (0.40) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2015129 | 0.79 | OPA1 (0.41) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2015795 | 0.78 | HTR2A (0.43) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2016690 | 0.77 | GSK3B (0.40) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2020158 | 0.77 | OPA1 (0.40) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2015557 | 0.77 | OPA1 (0.41) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2018145 | 0.77 | OPA1 (0.39) | HTR2AHTR2CHPGDOPA1EIF5B | |
| SCHEMBL2017097 | 0.75 | OPA1 (0.39) | HTR2AHTR2CHPGDOPA1EIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563567-B2 | Substituted heterocyclic compounds | ARQULE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563567-B2 | Substituted heterocyclic compounds | ARQULE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2011082266-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160237-A1 | Substituted Heterocyclic Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160237-A1 | Substituted Heterocyclic Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160237-A1 | Substituted Heterocyclic Compounds | MKI67, CCNC, NQO1 | HTR2A 1440/4885HTR2C 632/4885HPGD 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.